SLAMF7 immunotherapy
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-11 — Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis: cross-connection with elotuzumab-myelofibrosis: Elotuzumab is the prototypical anti-SLAMF7 monoclonal antibody; its phase II trial in JAK2-mutated MF represents the first clinical application of SLAMF7-directed immunotherapy in this disease. (novelty: 4)
Open questions
Related
Contributing findings
MPN Research Foundation Opens 2026 MPN Challenge Funding Cycle
06-jan-2026
novelty 2
per-area 2
introduces